吉西他滨联合顺铂对蒽环类及紫杉类耐药转移性乳腺癌的疗效观察.pdfVIP

第13卷4期 天 津 医 科 大 学 学 报 V0I_13．No．4 546 2007年 12月 JOURNAL OF TIANJ1NMEDlCAL UNIVERS1TY Dec．2007 吉西他滨联合顺铂对蒽环类及紫杉类 耐药转移性乳腺癌的疗效观察 王 忱，佟仲生，郝希山 (天津医科大学肿瘤医院乳腺内科，天津 300060) [摘要]目的：观察吉西他滨联合顺铂(GP)方案治疗葸环类及紫杉类均耐药转移性乳腺癌的疗效和不良反应。方法：采 用吉西他滨联厶J顷铂方案治疗蒽环类及紫杉类均耐药转移性乳腺癌35例。吉西他滨1 000mg／m2静脉滴注。第1、8 天给予；顺铂80 mgCm 分3次静脉滴注，第1-3天给予。化疗以21 d为1个周期，至少应用2个周期。结果：本组患者 治疗有效率为37．1％(13／35)，中位生存时间为15．1(95％CI 13．2～17．0)个月，中位疾病进展时间为5．7个月。1年生存 率为65．7％。无化疗相关死亡病例，主要不良反应为骨髓抑制及胃肠道反应。结论：吉西他滨联合顺铂方案对葸环类 及紫杉类均耐药的转移性乳腺癌有较好的近期疗效，不良反应可耐受，为有效的解救方案。 [关键词]乳腺肿瘤；转移；吉西他滨；疗效；不良反应 [中图分类号]R737．9 [文献标识码]A [文章编号]1006—8147(2007)04—0546—03 Gemcitabine combined with cisplatin in the treatment of anthracycline- and taxane—-resistant metastatic breast cancer WANG Chen，TONG Zhong-sheng，HAO Xi—shan (Department ofMedical Oncology ofBreast Cancer，Cancer Hospital，Tianjin Medical University，Tianjin 300060，China) ABSTRACT Objective：To investigate the efficacy and toxicity of GP(gemcitabine combined cisplatin) regimen as chemotherapy for anthracycline—and taxane-resistant metastatic breast cancer(MBC)． Methods：Thirty-five patients were treated by GP regimen．All had failures or relapse after previous treatment with anthracyclines and taxanes．GP：1 000 mgJm。gemcitabine on day 1 and 8．and 80 mg／m DDP infusion on day 1，2 and 3．Treatments were repeated every 21 days and all patients received at least 2 cycles of chemotherapy．Overall response rate(RR)，overall survival time(ST)，time to progression(rrrP) and 1-year survival of the patients were assessed after treatment．Results：The overall response rate， median ST，median，rI1P was 37．1％，15．1(95％CI 13．2-17．0)months and 5．7 months，respe